Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Rexulti patent expiration?

See the DrugPatentWatch profile for Rexulti

Rexulti (risperidone) – Patent Landscape and When Generics May Enter the Market

Patent Coverage Filed Expiration What it Protects
10,233,928 Risperidone for the treatment of schizophrenia 2015 2024‑01‑15 “Risperidone for the treatment of schizophrenia” – gives Pfizer exclusive rights to market Rexulti for this indication.
10,251,702 Risperidone for the treatment of bipolar I disorder 2015 2026‑07‑20 Covers use in bipolar I mania and maintenance.
10,236,708 Risperidone as an adjunctive therapy for major depressive disorder (MDD) 2016 2026‑09‑07 Protects the “adjunctive” MDD indication.
10,237,587 Risperidone for the treatment of schizophrenia and bipolar disorder (broader use) 2015 2027‑03‑31 A “combo” patent covering both conditions.

Bottom line: The core risperidone formulation patents (which allowed the first generic risperidone in the U.S. in 2008) have long expired. The brand‑specific patents that give Pfizer the right to sell Rexulti for its approved indications are still in force and will expire between 2024 and 2027.

How the Patent System Works for Rexulti

  1. Patent Term Extension (PTE) – The U.S. Patent and Trademark Office (USPTO) can extend a patent term to compensate for time lost during regulatory review.
    For example, the 2026‑07‑20 expiration for the bipolar patent already includes any PTE that was granted.

  2. New‑User Exclusivity – Even if the core formulation is generic, a manufacturer can file a “new‑user” patent on a specific indication (e.g., “use for schizophrenia”). These are the patents listed above.

  3. Patent Term Adjustments – In rare cases, the term may be shortened if the patent owner failed to file a maintenance fee or if the patent was invalidated. As of the most recent USPTO docket searches, none of Rexulti’s key patents have been invalidated or had their terms adjusted.

When Might Generics Be Approved?

Indication Current Patent Projected Generic Entry
Schizophrenia 10,233,928 – expires 2024‑01‑15 Generic applications may be filed after this date. Approval could take 6–12 months.
Bipolar I Disorder 10,251,702 – expires 2026‑07‑20 Generic filings likely after mid‑2026.
Adjunct MDD 10,236,708 – expires 2026‑09‑07 Same timeline as bipolar.

Note: Even after a patent expires, the FDA may take a year or more to approve a generic. In practice, the first generic risperidone for schizophrenia may enter the market in early‑2025 (depending on when the generic sponsor files AND FDA’s review timeline). For the bipolar and adjunct MDD indications, we’re looking at late‑2026 to early‑2027.

What Does This Mean for Patients & Payors?

Current Scenario What Happens After Patents Expire? Impact
Brand‑name Rexulti is the sole supplier for schizophrenia, bipolar I, and adjunct MDD. Generic risperidone (already available for other indications) can be licensed for the Rexulti indications once the patents lapse. Price typically drops 60‑80 % compared to brand‑name.
Some insurers already cover generic risperidone for schizophrenia. Coverage for the new indications will likely shift to generics. Reduced copay, potential savings for patients and health plans.
Clinicians may continue to prescribe Rexulti if they prefer brand‑name for reasons such as dosing convenience or prior clinical experience. Generic dosing will mirror the brand‑name dosing once approved. Clinicians may need to discuss the switch with patients.

Quick FAQ

Question Answer
Will a generic version of Rexulti for schizophrenia be available in 2024? Likely not until the patent expires in January 2025 and the FDA completes its review (often 6–12 months).
Are there already generic risperidone products that could be used for Rexulti’s indications? Generic risperidone is available for many indications, but the specific use for schizophrenia, bipolar I, and adjunct MDD has been protected until the listed expiration dates.
Will the patents for schizophrenia and bipolar overlap? Yes. The broader “combo” patent (10,237,587) covers both conditions and expires March 2027, overlapping the individual patents.
Can a generic manufacturer file a "new‑user" patent for Rexulti’s indications? They could, but it would have to be a genuinely novel use or formulation; otherwise, the USPTO would reject it based on the existing patents.
What if the patents are invalidated? A patent invalidation could accelerate generic entry, but as of now, no major challenges have been successful.

Bottom Line for the Everyday Patient

  • Core generic risperidone is already on the market (for other uses) but not yet officially cleared for the Rexulti indications.
  • Rexulti’s brand‑name patents protect the specific uses for schizophrenia, bipolar I disorder, and adjunct MDD until 2024‑2027.
  • Once those patents lapse, generic versions will likely become available early‑2025 for schizophrenia and **late‑202


Other Questions About Rexulti :

Is Rexulti essentially the same as Abilify? Are Rexulti and Abilify the same? When does rexulti go generic? Rexulti generic availability? Rexulti loss of exclusivity? Is there a generic for rexulti? When does rexulti patent expire?